JNJ•benzinga•
Johnson & Johnson Says First Results From Cohort 4 Of Phase 2B Sunrise-1 Study Show Potential Of TAR-200 Monotherapy In Patients With Papillary-only, High-risk Non-muscle Invasive Bladder Cancer
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on April 21, 2025 by benzinga